Tianjin Wei Kai Biological Engineering Co., Ltd. was incorporated in 2009, is located in Tianjin Binhai New Area Tanggu marine hi tech Development Zone Science and Technology Park, is China Regenerative Medicine International Limited (Hongkong Stock Exchange Stock Code: 8158) Affiliated Companies
Tianjin weikai biological engineering co., LTD is a high-tech innovation-oriented enterprise integrating technology R&D (R&D), technical service (CRO) and Product Development. Tianjin WeiKai focus on research and development cells and three-dimensional culture of stem cells and biological processing technology and its industrialization, the core technology including cell and stem cell separation, purification, amplification, storage and transportation, human stem cells three-dimensional cultivation and control, the establishment of organizational model and in vitro cell function of the human body detection, etc. Tianjin weikai was founded in 2009 with a registered capital of 12 million yuan. Currently, there are 1200 square meters of laboratory, including cell culture lab, biological material preparation room, stem cell bank, bioreactor production workshop. In addition, the company has advanced cell culture and function detection equipment.
Tianjin weikai has a leading innovation team in China, with 23 employees in the technical center, including 9 doctors, all of whom are British doctors or postdocs and 10 masters. Moreover, WeiKai has established a wide range of partners at home and abroad and the information network, is now with the stem cell institute at Oxford University, Oxford, institute of biomedical engineering, university of Cambridge department of physiology, Taiwan chang gung university school of medicine, Chinese academy of sciences and the domestic famous universities such as unit established close relations of cooperation.
WeiKai has now established a "3 d perfusion type cell culture platform, with the help of perfusion type three-dimensional micro bioreactor successfully established human liver, human tumor, rat liver, heart, nerve and islet cell model in vitro. Can provide the liver, myocardial and neurotoxic detection, anticancer drugs and diabetes drug efficacy detection technology services.
The strategic partner of tianjin weikai bioengineering co., LTD., UK Zyoxel, is a university of Oxford University, mainly engaged in the development of new drug development and pre-clinical technology. Its 3 d, which is used in the first phase of development of cells perfusion culture of hardware - TissueFlex three-dimensional perfusion bioreactor micro, can greatly improve the efficiency of drug development, is an effective tool for drug screening and toxicity test. Tianjin weikai and Zyoxel cooperate fully and are responsible for the exclusive sales of Zyoxel products in China. Zyoxel will develop markets in Europe and the United States and provide technical support for the establishment of cellular 3d models.